Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  letrozole
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 103 for your search:
Start Over
Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000068583, NOVARTIS-CFEM345A-US10, NCT00014638
Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors
Phase: Phase IV
Type: Diagnostic, Supportive care, Treatment
Status: Closed
Age: 40 to 65
Sponsor: Other
Protocol IDs: 2004/949, NCT00111241
Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CFEM345EBR01, NCT00237133
Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 50 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CFEM345DUS59, NCT00688909
Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole Therapy
Phase: Phase IV
Type: Supportive care, Treatment
Status: Closed
Age: 45 and over
Sponsor: Other
Protocol IDs: KBCSG002, NCT00913016
Pharmacology of Adjuvant Hormonotherapy in Breast Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 09 SEIN 09, NCT01127295
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001JIL05, NCT01231659
Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 11 SEIN 09, NCT01553903
Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 11SEIN12, NCT01612871
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: CDR0000456382, ACOSOG-Z1031, CALGB-ACOSOG-Z1031, SDC1, NCT00265759
Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446GDE19, NCT00375752
Letrozole After Tamoxifen in Treating Women With Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: MA17, U10CA025224, CAN-NCIC-MA17, CALGB-49805, E-JMA17, EORTC-10983, IBCSG-BIG97-01, NCCTG-JMA17, SWOG-JMA17, JRF-Vor-Int-10, NCCTG-CAN-MA17, SWOG-CAN-MA17, CDR0000065921, JMA17, NCT00003140
Phase III Randomized Comparison Study of Letrozole Versus Tamoxifen as First-Line Therapy in Postmenopausal Women with Stage IIIB, Metastatic, or Recurrent Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NOVARTIS-2026701025, CGS-20267, NCI-V98-1388
Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 30 and over
Sponsor: Other
Protocol IDs: CDR0000067451, IBCSG-18-98, DAN-DBCG-IBCSG-1-98, FRE-FNCLCC-IBCSG-1-98, EU-99022, NOVARTIS-2026703019, BIG-1-98, IBCSG-1-98, BIG-I-98, NCT00004205
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: EGF30008, NCT00073528
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Biomed 777-CLP-29, NCT00044291
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: CDR0000413877, NCCTG-N03CC, N03CC, NCT00107263
Assessing Impact of Loco-regional Treatment on Survival in Metastatic Breast Cancer at Presentation
Phase: Phase III
Type: Treatment
Status: Closed
Age: 21 to 65
Sponsor: Other
Protocol IDs: TMH/153/2004, NCT00193778
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 50 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CFEM345D2407, NCT00171704
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Closed
Age: 18 to 75
Sponsor: NCI
Protocol IDs: NCI-2009-00707, CDR0000472066, ECOG-PACCT-1, PACCT-1, U10CA180820, U10CA021115, NCT00310180
Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CFEM345DFR04, NCT00329940
Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: CFEM345EGB07, NCT00330317
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CFEM345DDE09, NCT00332709
Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CFEM345DDE10, NCT00332852
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age (postmenopausal)
Sponsor: NCI, Other
Protocol IDs: NSABP B-42, U10CA012027, NCT00382070
Start Over